Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew S Robertson

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
American Journal of Law & Medicine|November 1, 2017
Preserving an Incentive for Global Health R&D: The Priority Review Voucher Secondary MarketAndrew S Robertson
Therapeutic Innovation & Regulatory Science|December 10, 2020
Impact of FDA-Required Cardiovascular Outcome Trials on Type 2 Diabetes Clinical Study Initiation From 2008 to 2017Cameron M Kieffer, Andrew S Robertson
Therapeutic Innovation & Regulatory Science|July 18, 2019
Impact of FDA-Required Cardiovascular Outcome Trials on Type 2 Diabetes Clinical Study Initiation From 2008 to 2017Cameron M Kieffer, Andrew S Robertson
JAMA Internal Medicine|June 12, 2023
Approval of Drugs With Unmet Trial End PointsIndranil Bhattacharya, Iraj Daizadeh, Andrew S Robertson
Nature Reviews. Drug Discovery|June 3, 2020
Supporting a data-driven approach to regulatory intelligenceAndrew S Robertson, Alexis Reisin Miller, Felipe Dolz
Plos Neglected Tropical Diseases|September 7, 2012
The impact of the US priority review voucher on private-sector investment in global health research and developmentAndrew S Robertson, Rianna Stefanakis, Don Joseph, et al.
Plos Neglected Tropical Diseases|November 13, 2012
Analysis of neglected tropical disease drug and vaccine development pipelines to predict issuance of FDA priority review vouchers over the next decadeRianna Stefanakis, Andrew S Robertson, Elizabeth L Ponder, et al.
Therapeutic Innovation & Regulatory Science|December 10, 2020
FDA Reported Use of Patient Experience Data in 2018 Drug ApprovalsCameron M Kieffer, Alexis Reisin Miller, Benjamin Chacko, et al.
Therapeutic Innovation & Regulatory Science|October 11, 2019
FDA Reported Use of Patient Experience Data in 2018 Drug ApprovalsCameron M Kieffer, Alexis Reisin Miller, Benjamin Chacko, et al.
The Journal of Experimental Biology|May 27, 2011
The influence of trout cardiac troponin I and PKA phosphorylation on the Ca2+ affinity of the cardiac troponin complexKelly P Kirkpatrick, Andrew S Robertson, Jordan M Klaiman, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
American Journal of Law & Medicine|November 1, 2017
Preserving an Incentive for Global Health R&D: The Priority Review Voucher Secondary MarketAndrew S Robertson
Therapeutic Innovation & Regulatory Science|December 10, 2020
Impact of FDA-Required Cardiovascular Outcome Trials on Type 2 Diabetes Clinical Study Initiation From 2008 to 2017Cameron M Kieffer, Andrew S Robertson
Therapeutic Innovation & Regulatory Science|July 18, 2019
Impact of FDA-Required Cardiovascular Outcome Trials on Type 2 Diabetes Clinical Study Initiation From 2008 to 2017Cameron M Kieffer, Andrew S Robertson
JAMA Internal Medicine|June 12, 2023
Approval of Drugs With Unmet Trial End PointsIndranil Bhattacharya, Iraj Daizadeh, Andrew S Robertson
Nature Reviews. Drug Discovery|June 3, 2020
Supporting a data-driven approach to regulatory intelligenceAndrew S Robertson, Alexis Reisin Miller, Felipe Dolz
Plos Neglected Tropical Diseases|September 7, 2012
The impact of the US priority review voucher on private-sector investment in global health research and developmentAndrew S Robertson, Rianna Stefanakis, Don Joseph, et al.
Plos Neglected Tropical Diseases|November 13, 2012
Analysis of neglected tropical disease drug and vaccine development pipelines to predict issuance of FDA priority review vouchers over the next decadeRianna Stefanakis, Andrew S Robertson, Elizabeth L Ponder, et al.
Therapeutic Innovation & Regulatory Science|December 10, 2020
FDA Reported Use of Patient Experience Data in 2018 Drug ApprovalsCameron M Kieffer, Alexis Reisin Miller, Benjamin Chacko, et al.
Therapeutic Innovation & Regulatory Science|October 11, 2019
FDA Reported Use of Patient Experience Data in 2018 Drug ApprovalsCameron M Kieffer, Alexis Reisin Miller, Benjamin Chacko, et al.
The Journal of Experimental Biology|May 27, 2011
The influence of trout cardiac troponin I and PKA phosphorylation on the Ca2+ affinity of the cardiac troponin complexKelly P Kirkpatrick, Andrew S Robertson, Jordan M Klaiman, et al.
Pageof 2